184851-16-9

Usage

Uses

Used in Organic Synthesis:
[(1S,3E,5R)-3-[(2E)-2-[(1R,7aR)-7a-methyl-1-[(E,1R,4R)-1,4,5-trimethylhex-2-enyl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-5-[tert-butyl(dimethyl)silyl]oxy-2-methylene-cyclohexoxy]-tert-butyl-dimethyl-silane is used as a reagent for the synthesis of various organic compounds due to its multiple functional groups and chiral centers.
Used in Coordination Chemistry:
[(1S,3E,5R)-3-[(2E)-2-[(1R,7aR)-7a-methyl-1-[(E,1R,4R)-1,4,5-trimethylhex-2-enyl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-5-[tert-butyl(dimethyl)silyl]oxy-2-methylene-cyclohexoxy]-tert-butyl-dimethyl-silane may be used as a ligand in coordination chemistry, potentially forming complexes with metal ions for applications in catalysis or material science.
Used in Material Science:
[(1S,3E,5R)-3-[(2E)-2-[(1R,7aR)-7a-methyl-1-[(E,1R,4R)-1,4,5-trimethylhex-2-enyl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-5-[tert-butyl(dimethyl)silyl]oxy-2-methylene-cyclohexoxy]-tert-butyl-dimethyl-silane's unique structure and functional groups may allow it to be used in the development of new materials with specific properties, such as polymers or coatings with tailored characteristics.
(Note: The specific applications mentioned above are hypothetical and would require further research and development to confirm their feasibility and effectiveness.)

Upstream product

• 50-14-6 Calciferol 
• 87680-65-7 (S)-3-[(1R,3aS,7aR)-7a-Methyl-1-((E)-(1R,4R)-1,4,5-trimethyl-hex-2-enyl)-octahydro-inden-(4E)-ylidenemethyl]-2,2-dioxo-2,3,4,5,6,7-hexahydro-1H-2λ⁶-benzo[c]thiophen-5-ol 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 170081-43-3 SO2-adduct of 3(S)-<(tert-butyldimethylsilyl)oxy>-9,10-secoergosta-5,7(E),10(19),22(E)-tetraene 
• 115540-27-7 1(S),3(R)-3-(tert-butyldimethylsilyl)-9,10-secoergosta-5(E),7(E),10⁽¹⁹⁾,22(E)-tetraene-1-ol 
• 112670-78-7 1(S),3(R)-3-(tert-butyldimethylsilyl)-9,10-secoergosta-5(E),7(E),10⁽¹⁹⁾,22(E)-tetraene-1-ol 
• 125091-81-8 (2S,5S)-2-{(1R,3aS,7aR)-4-[2-[(3S,5R)-3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-2-methylene-cyclohex-(Z)-ylidene]-eth-(E)-ylidene]-7a-methyl-octahydro-inden-1-yl}-5,6-dimethyl-4-(toluene-4-sulfonyl)-heptan-3-ol 
• 115540-28-8 1(S),3(R)-bis(tert-butyldimethylsilyloxy)-9,10-secoergosta-5(E),7(E),10⁽¹⁹⁾,22(E)-tetraene 
• 74007-20-8 1α-hydroxy-5,6-trans-vitamin D₂ 
• 111594-58-2 (1R,7aR)-4-[2-[(3S,5R)-3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-2-methylene-cyclohex-(E)-ylidene]-eth-(E)-ylidene]-7a-methyl-1-((E)-(1R,4R)-1,4,5-trimethyl-hex-2-enyl)-octahydro-indene 
• 125091-79-4 (S)-2,3-dimethylbutyl p-tolyl sulphone 
• 125091-77-2 (2S)-2,3-dimethylbutyl (S)-p-tolyl sulphoxide 
• 112924-91-1 (5Z,7E)-(1S,3R,20S)-1,3-bis<(tert-butyldimethylsilyl)oxy>-9,10-seco-22,23-dinor-5,7,10(19)-cholatrien-24-al 
• 125091-76-1 2,3-dimethylbutylmagnesium bromide 

Downstream Products

• 170081-46-6 (6S)- and (6R)-SO₂ adducts of 1(S),3(R)-bis(tert-butyldimethylsilyloxy)-9,10-secoergosta-5(E),7(E),10⁽¹⁹⁾,22(E)-tetraene 
• 112790-51-9 (6R)-SO₂ adduct of 1(S),3(R)-bis(tert-butyldimethylsilyloxy)-20(S)-formyl-9,10-secopregna-5,7(E),10⁽¹⁹⁾-triene 
• 112670-80-1 (6S)-SO₂ adduct of 1(S),3(R)-bis(tert-butyldimethylsilyloxy)-20(S)-formyl-9,10-secopregna-5,7(E),10⁽¹⁹⁾-triene 
• 266686-81-1 C₃₄H₆₀O₅SSi₂ 
• 169218-36-4 (1β,3β-5Ζ,7Ε)-9,10-secocholesta-5,7,10(19)-triene-1,3,24-triol 
• 140710-98-1 (1S),3(R)-bis<(tert-butyldimethylsilyl)oxy>-9,10-secocholesta-5(E),7(E),10(19)-trien-25-ol 
• 1255151-20-2 1(S),3(R)-bis(tert-butyldimethylsilyloxy)-20(R)-(3′-isopropyl-3′-oxypropyl)-9,10-secopregna-5(E),7(E),10(19)-triene 
• 266686-81-1 (6S)- and (6R)-SO₂ adducts of 1(S),3(R)-bis(tert-butyldimethylsilyloxy)-20(S)-formyl-9,10-secopregna-5,7(E),10⁽¹⁹⁾-triene 
• 57333-96-7 tacalcitol 
• 57333-95-6 1alpha,24(S)-Dihydroxyvitamin D₃ 

Relevant academic research and scientific papers

A calcitriol synthesis of intermediates method

The invention discloses a calcitriol intermediate compound preparation method, which belongs to the drug synthesis and organic compound synthesis technology field. The invention wide sources of raw materials are easy, simple and safe operation, environmen

Enantiomeric impurity PY2 of tacalcitol and preparation method and application thereof

The invention discloses an enantiomeric impurity PY2 of tacalcitol, i.e., (1 alpha, 3 beta, 5Z, 7E, 24S)-9,10-Secocholesta-5,7,10(19)-triene-1,3,24-triol, and a preparation method thereof, and belongsto the technical field of chemical pharmaceutical. The high-purity relevant impurity PY2 of the tacalcitol, which is disclosed by the invention, can be used as an impurity standard substance in the tacalcitol finished product detection analysis so as to promote accurate positioning and nature determination of the tacalcitol finished product detection analysis on the impurity and benefit reinforcement of control on the impurity, thereby improving quality of a tacalcitol finished product. The method provided by the invention has the advantages that the raw materials are cheap and easy to obtain, the operation is simple, the reproducibility is good in and the HPLC (High Performance Liquid Chromatography) purity is greater than or equal to 99.5%.

Tacilol isomer impurity PY3 and preparation method and use thereof

The present invention discloses a tacilol isomer impurity PY3 and a preparation method thereof, and belongs to the chemical pharmaceutical technical field. The tacilol isomer impurity PY3 is (1beta, 3beta, 5Z, 7E, 22E)-9,10-secoergosta-5, 7, 10 (19), 22-tetraen-1,3-diol. The high-purity alfacalcidol-related impurity PY3 can be used as an impurity standard in the detection and analysis of an alfacalcidol finished product, accurate positioning and characterization of impurities in the detection and analysis of the alfacalcidol finished product can be promoted, enhancement of control of the impurities can be facilitated, and the quality of the alfacalcidol finished product can be improved. The method has the advantages of low cost and easy availability of raw materials, simple operation and good reproducibility, and the HPLC purity is >=99.5%.

Synthesis of 24(28)-methylene-1α-hydroxyvitamin D3, a novel vitamin D3 analogue

24(28)-Methylene-1α-hydroxyvitamin D3 was synthesised in 13 steps from vitamin D2. The key step of the synthesis involved the Wittig-Horner olefination of a nor-vitamin D2 aldehyde with diethylphosphono-3-methyl-2-butanone

Development of an improved process for doxercalciferol via a continuous photochemical reaction

Doxercalciferol (1α-hydroxyvitamin D2) is a commercially approved vitamin D derivative used to treat chronic kidney disease (CKD) patients whose kidneys cannot metabolically introduce a hydroxyl group at C1. A new process for the production of doxercalcif

CONTINUOUS PHOTOLYTIC PROCESS FOR THE PREPARATION OF VITAMIN D RELATED SUBSTANCES

The present application provides a novel method for generation of a vitamin D2 compound using a continuous flow photoisomerization reactor. A compound represented by formula I: [structure] as further defined herein, is mixed with a solvent and a sensitize

Synthesis of a Biologically Active Vitamine-D2 Metabolite

The synthesis of 1α,25,28-trihydroxyvitamin-D2 (1) from vitamin-D2 is described.Approaches to the upper side-chain synthon via the chiral sulfone 15, prepared either through the enzymatic resolution of 10 or the opening of the optica

Allylic Hydroxylation of Vitamin D with Mercury(II) trifluoroacetate

Treatment of vitamin D with Hg(OCOCF3)2 results in formation of the isovitamin D derivative 2, which can be converted into C-1 hydroxylated 5E vitamin D derivatives.Key Words: Allylic hydroxylation; mercurytrifluoroacetate; isovitamin D derivatives; vitamin D derivatives; 199Hg NMR.

A Convenient Synthesis of (24S)-1-α-Hydroxyvitamin D2

A new method was developed for the synthesis of (2R)- and (2S)-2,3-dimethylbutyl p-tolyl sulphone from a chiral sulphinate ester, and applied to the synthesis of (24S)-1α-hydroxyvitamin D2; this new 24-epimer of vitamin D2 has a distinct biological activi